Cigna Group (CI) Q2 FY26 earnings call: guidance and Q&A

How will earnings growth progress within Evernorth, specifically for Specialty & Care and Pharmacy Benefits, and how is investment pace impacting this?

Specialty & Care exceeded expectations due to utilization growth, biosimilar/specialty generic adoption, and operating efficiencies. Specialty generic penetration was over 80% for newer products. This benefit was earlier than expected, so the magnitude won't repeat in H2. Pharmacy Benefit Services saw moderation in GLP-1 growth, which is expected to continue, offsetting some of the Specialty strength.

“We experienced it earlier than expected. So the magnitude of the benefit we saw in the second quarter is not expected to repeat at the same level in the third and fourth quarters, but we still expect strong results as we look to the back half of the year for Specialty & Care.”

asked by Stephen Baxter · answered by Ann Dennison

Discuss PBM selling season renewals and new business wins, and incremental opportunities within Specialty, including carve-outs or new business.

Affordability and customer experience are key themes. PBM closed 2026 with over 97% retention, and 2027 preliminary indicators suggest mid-90s or higher. 2027 new business is strong, exceeding the prior two selling seasons combined. The new rebate-free Signature model is generating interest for 2028. Specialty & Care benefits from secular tailwinds, leading to more patients using specialty drugs, and growth in hospital/health system space through fee-based offerings and Shields Health Solutions synergies.

“Total new business already secured is above the prior 2 selling seasons combined. So a very strong '27 new business performance.”

asked by Lisa Gill · answered by Brian Evanko

Is the commercial cost trend consistent with high single digits? Is GLP-1 moderation helping commercial cost trends? And what was the impact of risk adjustment?

Medical cost trends remain persistently elevated at high single-digit levels, with no significant deceleration or acceleration. Some favorability was seen in outpatient trends, but not enough to call it a break. GLP-1 moderation had a very modest benefit on Cigna Healthcare, but the overall financial impact was immaterial as only 15-20% of the employer book covers GLP-1s for weight management. Risk adjustment results were consistent with expectations and not a driver for the quarter.

“We continue to see high single-digit type cost trends. So persistently elevated cost trend levels, not a significant deceleration and no acceleration fortunately as well.”

asked by Albert Rice · answered by Brian Evanko

Explain why biosimilars benefit Specialty but are a headwind for Pharmacy Benefits. Also, comment on Cigna Healthcare's exposure to IDR and stop loss.

Stronger biosimilar/specialty generic adoption shifts economics from Pharmacy Benefit Services to Specialty & Care, resulting in an overall net benefit to Evernorth. Drug costs are lower, so revenue line doesn't proportionally increase. On IDR, management supports consumer protection but sees abuses, with unsustainable volume and settlements favoring providers, costing the industry $15 billion in 2025. Cigna's impact has been manageable. Stop loss is tracking in line with expectations, with stable frequency trends and high-cost payments.

“The economic shift from pharmacy benefit services to the Specialty & Care line. And there's also -- because drug costs are lower, you'll see a sort of not a proportional increase in the revenue line. So overall, I'd say, overall net benefit to Evernorth as a whole, lower results in Pharmacy Benefit Services and higher results in Specialty & Care and sort of how it all comes together.”

asked by Charles Rhyee · answered by Ann Dennison

Elaborate on the earnings shift between Specialty and PBM due to biosimilars, and quantify the proportionality of this shift.

Evernorth's Q2 performance was slightly ahead of expectations due to faster biosimilar/specialty generic penetration in Specialty & Care and modestly lower GLP-1 volume growth. The biosimilar benefit was earlier than expected and won't repeat at the same magnitude in H2. GLP-1 moderation is expected to continue. Overall, PBS is tracking modestly below earlier assumptions due to economic shifts, while Specialty & Care is performing above expectations. The overall strength of the enterprise allowed for a raised full-year EPS outlook despite these offsetting dynamics.

“So essentially, the outperformance in the second quarter is given back in the form of slightly lower GLP-1 volumes in the back half of the year. So that's how I encourage you to think about the overall segment.”

asked by Justin Lake · answered by Brian Evanko

How will the planned exit from the exchange business free up capital and resources? Are there other end markets or lines of business Cigna is emphasizing, such as national accounts or large group, for redeployment?

Cigna is pleased with its positioning in Cigna Healthcare and does not feel compelled to enter different end markets. It will continue to invest in the U.S. employer business, particularly the under 500 Select segment, and leverage its stop-loss offerings. The International Health business is also a strong performer. The ACA exchange exit will result in positive but below-target margins for 2026, some stranded overhead, and a modest capital release, but nothing significant.

“So do you not feel compelled to get into other elements of the health plan space at this point. We're quite pleased with what we have in terms of the current franchise.”

asked by Scott Fidel · answered by Brian Evanko

Discuss the growth and momentum seen in partnering with hospitals and health systems through Shields, and the solutions resonating in that market.

The specialty pharmacy market is a $500 billion TAM with high single-digit secular growth. Cigna is a leader in the 60% direct-to-patient segment via Accredo. The remaining 40% is provider-administered drugs, where Shields Health Solutions focuses on providing management services to health systems for their own specialty pharmacies. Shields serves over 80 health systems (1,000+ hospitals). Future growth comes from secular market growth, low penetration of management companies, and mutual value creation opportunities between Shields and Evernorth. This is an area of continued investment.

“Shields is specifically focused on providing management services to health systems to operate their own specialty pharmacies, and Shield is the clear leader in the management services space. They serve over 80 sizable health systems, representing more than 1,000 hospitals across 50 states.”

asked by Jason Cassorla · answered by Brian Evanko

Discuss Cigna's decision to end employee coverage for Wegovy/Zepbound, if this is reflected in mid-year updates/2027 renewals, and how it interacts with EnCircle growth trends.

Cigna discontinued financial support for GLP-1s for weight management in its employee health plan due to affordability and broader availability of options, offering a supplemental discount program instead. This decision reflects challenges clients face, with a slight downtick in employers covering GLP-1s for weight management, creating a modest headwind for 2026. EnCircle remains effective for employers who cover GLP-1s, but the space will continue to evolve with ongoing debate over funding.

“So we did make the difficult decision during 2026 to discontinue financial support for GLP-1 drugs for weight management within our own employee health plan.”

asked by Sarah James · answered by Brian Evanko